Investigational T-cell Receptor Therapy Achieves Encouraging Clinical Responses in Multiple Myeloma Patients, Penn-led Study Finds

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person’s own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).